Jefferies Starts OraSure Technologies (OSUR) at Buy
Tweet Send to a FriendGet Alerts OSUR Hot Sheet
Price: $4.41 +1.38%
Rating Summary:
11 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 21 | Down: 24 | New: 29
Rating Summary:
11 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 21 | Down: 24 | New: 29
Trade OSUR Now!
Jefferies initiates coverage on OraSure Technologies (NASDAQ: OSUR) with a Buy rating and a price target of $14.00.
Following years of substantial investments, OSUR is on the verge of capitalizing on the commercialization of two major new product launches that Jefferies forecasts will drive over 20% revenue CAGR over the next several years, notes today’s report. The biggest game changer of the two products is an at-home HIV test.
“Our formal forecasts assume OSUR captures ~10% of the addressable market opportunity by 2015, which we view as highly conservative in the context of its >60% share in its core professional rapid HIV market as well as what we perceive will be an extended period of exclusivity,” said analyst Jon Wood.
“For perspective, each 10% of incremental market penetration is worth $1.25 of upside to our formal price target,” noted Wood.
For an analyst ratings summary and ratings history on OraSure Technologies click here. For more ratings news on OraSure Technologies click here.
Shares of OraSure Technologies closed at $9.75 yesterday, with a 52 week range of $6.29-$14.01.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Following years of substantial investments, OSUR is on the verge of capitalizing on the commercialization of two major new product launches that Jefferies forecasts will drive over 20% revenue CAGR over the next several years, notes today’s report. The biggest game changer of the two products is an at-home HIV test.
“Our formal forecasts assume OSUR captures ~10% of the addressable market opportunity by 2015, which we view as highly conservative in the context of its >60% share in its core professional rapid HIV market as well as what we perceive will be an extended period of exclusivity,” said analyst Jon Wood.
“For perspective, each 10% of incremental market penetration is worth $1.25 of upside to our formal price target,” noted Wood.
For an analyst ratings summary and ratings history on OraSure Technologies click here. For more ratings news on OraSure Technologies click here.
Shares of OraSure Technologies closed at $9.75 yesterday, with a 52 week range of $6.29-$14.01.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Deutsche Bank Upgrades Seagate (STX) to Buy; Sanmina (SANM) Cut to Sell, Flextronics (FLEX) & Fabrinet (FN) Cut to Hold
- Benchmark Boosts PT on R.R. Donnelley (RRD)
- Topeka Capital Starts CEVA Inc. (CEVA) at Buy
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, New CoverageRelated Entities
Jefferies & Co
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
